TTRX — Turn Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2023016 ·
Last close
$12.49
Market Cap
$379.29M
52W High
$26.50
52W Low
$2.57
ADV30
131,620
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,628,060 | -5,849,734 | 16,960,719 | 10,288,510 | 16,273,831 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 0 | — | -2,193,570 | 279,070 | 12,162,241 | 5,076,144 | 7,475,518 |
| Sep 2025 | — | — | — | — | — | — | — |
Balance + Analyst (yfinance extras)
Retained Earnings
$-20,764,985
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-1,366,524
Pretax Income TTM
$-1,240,415
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -5,858,648 | -3,194,080 | 12,162,241 | 7,475,518 | 4,686,723 | -2,562,901 |
| Dec 2024 | 0 | -1,797,124 | -1,768,415 | 2,048,889 | 2,226,321 | -177,432 | -1,361,305 |
| Dec 2023 | 0 | -2,308,149 | -2,292,267 | 2,013,560 | 1,927,792 | 85,768 | -1,377,680 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.15
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RZLT | Rezolute, Inc. | $377.22M | $3.90 | — |
| GALT | GALECTIN THERAPEUTICS INC | $393.31M | $3.90 | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $393.66M | $13.85 | — |
| IRD | Opus Genetics, Inc. | $396.01M | $4.76 | — |
| SPRY | ARS Pharmaceuticals, Inc. | $405.75M | $4.08 | — |
News headlines (Yahoo Finance, 1h cache)
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
2026-09-09 12:00 · Yahoo
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
2026-08-12 20:30 · Yahoo
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
2026-07-11 17:02 · Yahoo
Turn Therapeutics’ stock jumps on AD data and trial expansion
2026-07-08 11:17 · Yahoo
Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis
2026-07-07 12:56 · Yahoo
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
2026-07-07 12:05 · Yahoo
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
2026-07-06 20:01 · Yahoo
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
2026-06-01 12:30 · Yahoo
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-10 12:00 · Yahoo
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
2026-09-08 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.